510(k) device
EchoGo Amyloidosis (1.0)
Ultromics Limited · Adjunctive Cardiac Amyloidosis Status Indicator (SDJ, Class II) · First FDA decision Nov 15, 2024, newest Nov 15, 2024Heart failure
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
1
Naming "EchoGo"
MAUDE reports
0
Brand "EchoGo", since 2015
PubMed studies
16
Mentioning "EchoGo"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- EchoGo Amyloidosis (1.0)Breakthrough510(k)
K240860 · Decided Nov 15, 2024 · 232 days after receipt
Device type: Adjunctive Cardiac Amyloidosis Status Indicator (SDJ) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "EchoGo", any status and sponsor, newest update first.
Ultromics LtdNot on our public-company list
NCT04877899 · 250 participants (planned) · Start Oct 8, 2020 · Primary completion Mar 31, 2021
Device: EchoGo · For: Cardiotoxicity; Cancer
Sites: Edmonton, Canada
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "EchoGo", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SDJ
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "EchoGo"[tiab]. The summary above synthesizes these.
- Evaluating artificial intelligence-driven stress echocardiography analysis system (EASE study): A mixed method study.
Mahdavi M, Thomas N, Flood C, et al. · BMJ Open · 2024Research Support, Non-U.S. Gov't
- PROTEUS Study: A Prospective Randomized Controlled Trial Evaluating the Use of Artificial Intelligence in Stress Echocardiography.
Woodward G, Bajre M, Bhattacharyya S, et al. · Am Heart J · 2023Randomized Controlled Trial, Multicenter Study
- Utility of an Automated Artificial Intelligence Echocardiography Software in Risk Stratification of Hospitalized COVID-19 Patients.
Wang TKM, Cremer PC, Chan N, et al. · Life (Basel) · 2022
- Artificial intelligence calculated global longitudinal strain and left ventricular ejection fraction predicts cardiac events and all-cause mortality in patients with chest pain.
O'Driscoll JM, Tuttolomondo D, Gaibazzi N · Echocardiography · 2023Research Support, Non-U.S. Gov't
- Evaluating the Performance and Potential Bias of Predictive Models for Detection of Transthyretin Cardiac Amyloidosis.
Hourmozdi J, Easton N, Benigeri S, et al. · JACC Adv · 2025
- Evaluating the performance and potential bias of predictive models for detection of transthyretin cardiac amyloidosis.
Hourmozdi J, Easton N, Benigeri S, et al. · medRxiv · 2025Preprint
- Artificial intelligence based left ventricular ejection fraction and global longitudinal strain in cardiac amyloidosis.
Cotella JI, Slivnick JA, Sanderson E, et al. · Echocardiography · 2023
- Alignment Between Cardiologists and AI-Driven Diagnostic Systems: Mixed Methods Study.
Mahdavi M, White S, Hothi SS, et al. · J Med Internet Res · 2026
- Global Longitudinal Strain Is Associated with Mortality in Patients with Multiple Myeloma.
Cui Z, Castagna F, Hanif W, et al. · J Clin Med · 2023
- External validation of artificial intelligence for detection of heart failure with preserved ejection fraction.
Akerman AP, Al-Roub N, Angell-James C, et al. · Nat Commun · 2025Validation Study
- Left ventricular assessment with artificial intelligence increases the diagnostic accuracy of stress echocardiography.
O'Driscoll JM, Hawkes W, Beqiri A, et al. · Eur Heart J Open · 2022
- EchoGO: annotation-context-aware functional interpretation of transcriptomic data.
Escobar-Sierra C, Langschied F, Miller A, et al. · MethodsX · 2026
Other devices of this type
Also filed under product code SDJ.
- Us2.caEko.Ai Pte Ltd. D/B/A Us2.Ai · 510(k) 2025
- InVision Precision Cardiac AmyloidInVision Medical Technology Corporation · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.